The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ivolgin A.F.

Vishnevsky 3-rd Central Military Clinical Hospital, Ministry of Defense of Russia

Avseitseva T.Y.

Vishnevsky 3-rd Central Military Clinical Hospital, Ministry of Defense of Russia

Cervical dystonia: ways to improve the effectiveness of botulinum therapy

Authors:

Ivolgin A.F., Avseitseva T.Y.

More about the authors

Read: 14452 times


To cite this article:

Ivolgin AF, Avseitseva TY. Cervical dystonia: ways to improve the effectiveness of botulinum therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(6):137‑143. (In Russ.)
https://doi.org/10.17116/jnevro2020120061137

Recommended articles:

References:

  1. Albanese A, Abbruzzese G, Dressler D, Duzynski W, Khatkova S, Marti MJ, Mir P, Montecucco C, Moro E, Pinter M, Relja M, Roze E, Skogseid IM, Timerbaeva S, Tzoulis C. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol. 2015;262(10):2201-2213. https://doi.org/10.1007/s00415-015-7703-x
  2. Hallett M, Albanese A, Dressler D, Segal KR, Simpson DM, Truong D, Jankovic J. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94-114.  https://doi.org/10.1016/j.toxicon.2012.12.004
  3. Avenali M, Icco R De, Tinazzi M, Defazio G, Tronconi L, Sandrini G, C. Tassorelli C. Pain in focal dystonias — A focused review to address an important component of the disease. Parkinsonism Relat Disord. 2018;54:17-24.  https://doi.org/10.1016/j.parkreldis.2018.04.030
  4. Sethi KD, Rodriguez R, Olayinka B. Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia. J Med Econ. 2012;15:419-423.  https://doi.org/10.3111/13696998.2011.653726
  5. Marion MH, Humberstone M, Grunewald R, Wimalaratna S. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin. Pract Neurol. 2016;16(4):288-295.  https://doi.org/10.1136/practneurol-2015-001335
  6. Skogseid IM, Kerty E. The course of cervical dystonia and patient satisfaction with long-term botulinum toxin A treatment. Eur J Neurol. 2005;12:163-170.  https://doi.org/10.1111/j.1468-1331.2004.01053.x
  7. Reichel G. Cervical dystonia: a new phenomenological classification for botulinum toxin therapy. J Basal Ganglia. 2011;1(1):5-12.  https://doi.org/10.1016/j.baga.2011.01.001
  8. Tatu L, Jost WH. Anatomy and cervical dystonia: «Dysfunction follows form». J Neural Transm (Vienna). 2017;124(2):237-243.  https://doi.org/10.1007/s00702-016-1621-7
  9. Jost WH, Tatu L. Selection of Muscles for Botulinum Toxin Injections in Cervical Dystonia. Mov Disord Clin Pract. 2015;2(3):224-226.  https://doi.org/10.1002/mdc3.12172
  10. Finsterer J, Revuelta GJ. Anterocollis and anterocaput. Clin Neurol Neurosurg. 2014;127:44-53.  https://doi.org/10.1016/j.clineuro.2014.09.020
  11. Marion MH, Humberstone M, Grunewald R, Wimalaratna S. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin. Pract Neurol. 2016;16(4):288-295.  https://doi.org/10.1136/practneurol-2015-001335
  12. Kapandji A. The Physiology of the Joints: The Spinal Column, Pelvic Girdle and Head. 7th Edition (2019).
  13. Finsterer J, Maeztu C, Revuelta GJ, Reichel G, Truong D. Collum-caput (COL-CAP) concept for conceptual anterocollis, anterocaput, and forward sagittal shift. J of the Neurological Sciences. 2015;355(1):37-43.  https://doi.org/10.1016/j.jns.2015.06.015
  14. Reichel G, Stenner A, Jahn A. The phenomenology of cervical dystonia. Fortschr Neurol Psychiatr. 2009;77(5):272-277.  https://doi.org/10.1055/s-0028-1109416
  15. Hsiung GY, Das SK, Ranawaya R, Lafontaine A-L, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord. 2002;17(6):1288-1293. https://doi.org/10.1002/mds.10252
  16. Brashear A, Bergan K, Wojcieszek J, Siemers ER, Ambrosius W. Patients’ perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A. Mov Disord. 2000;15(1):150-153.  https://www.ncbi.nlm.nih.gov/pubmed/10634256
  17. Nijmeijer SW, Koelman JH, Standaar TSM, Postma M, Tijssen MAJ. Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography. Parkinsonism Relat Disord. 2013;19(5):533-538.  https://doi.org/10.1016/j.parkreldis.2013.01.018
  18. Jinnah HA, Goodmann E, Rosen AR, Evatt M, Freeman A, Factor S. Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. J Neurol. 2016;263(6):1188-1194. https://doi.org/10.1007/s00415-016-8136-x
  19. Comella C, Bhatia K. An international survey of patients with cervical dystonia. J Neurol. 2015;262(4):837-848.  https://doi.org/10.1007/s00415-014-7586-2
  20. Jinnah HA, Comella CL, Perlmutter J, Lungu C, Hallett M. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon. 2018;147:89-95.  https://doi.org/10.1016/j.toxicon.2017.09.004
  21. Orlova OR. Focal Dystonia: Current Diagnostic Approach and Use of Botulinum Toxin Treatment. Nervnye Bolezni. 2016;4:3-13. (In Russ.).
  22. Reichel G, Stenner A, Janh A. Cervical dystonia: clinical-radiological correlations and recommendations for the correction of botulinum therapy. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2012;112(1):73-79. Russian. PubMed PMID: 22678680.
  23. Mokina TV, Pavlov YuI, Zalyalova ZA. Possibilities of using computed tomography to treat mixed cervical dystonia with botulinum toxin type A. Neurology, neuropsychiatry, psychosomatics. 2016;8(2):68-73. (In Russ.). https://doi.org/10.14412/2074-2711-2016-2-68-73
  24. Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VSC, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-873.  https://doi.org/10.1002/mds.25475
  25. Dressler D, Pan L, Saberi FA. Antibody-induced failure of botulinum toxin therapy: re-start with low-antigenicity drugs offers a new treatment opportunity. Journal of Neural Transmission. 2018 Oct;125(10):1481-1486. https://doi.org/10.1007/s00702-018-1911-3
  26. Hefter H, Brauns R, Ürer B, Rosenthal D, Albrecht P. Effective long - term treatment with incobotulinumtoxin (Xeomin) without neutralizing antibody induction: a monocentric, cross - sectional study. Journal of Neurology. 2020 May;267(5):1340-1347. https://doi.org/10.1007/s00415-019-09681-7

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.